Brief: Atavistik Bio, Roche Enter Drug Discovery Collaboration
24/09/2026 12:08
BRIEF-Atavistik Bio, Roche Enter Drug Discovery Collaboration Sept 24 (Reuters) - ATAVISTIK BIO:
ATAVISTIK BIO - TO RECEIVE $70 MILLION UPFRONT WITH POTENTIAL MILESTONE PAYMENTS UP TO $1.9B PLUS TIERED ROYALTIES
ATAVISTIK BIO: ANNOUNCES STRATEGIC RESEARCH COLLABORATION WITH ROCHE TO DISCOVER AND DEVELOP NOVEL ALLOSTERIC THERAPEUTICS
Source text: ID:nGNX82ncTH
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 587785269;))
Recent news on Roche Holding AG
See all newsNovartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib
Brief: Roche Says Sefaxersen Achieved Statistically Significant 43.1% Reduction In Proteinuria In Interim Phase III Data
Brief: Zymeworks Signs Exclusive Global Licensing Deal With Roche For Cancer Drug ZW209
Zymeworks licenses experimental lung cancer drug to Roche in up to $813 million deal
DB ups Roche to 'buy' on positive oncology survey